-independent phospholipase A 2 (iPLA 2 ) subfamily of enzymes is associated with arachidonic acid (AA) release and the subsequent increase in fatty acid turnover. This phenomenon occurs not only during apoptosis but also during inflammation and lymphocyte proliferation. In this study, we purified and characterized a novel type of iPLA 2 from bovine brain. iPLA 2 was purified 4,174-fold from the bovine brain by a sequential process involving DEAE-cellulose anion exchange, phenyl-5PW hydrophobic interaction, heparin-Sepharose affinity, Sephacryl S-300 gel filtration, Mono S cation exchange, Mono Q anion exchange, and Superose 12 gel filtration. A single peak of iPLA 2 activity was eluted at an apparent molecular mass of 155 kDa during the final Superose 12 gel-filtration step. The purified enzyme had an isoelectric point of 5.3 on twodimensional gel electrophoresis (2-DE) and was inhibited by arachidonyl trifluoromethyl ketone (AACOCF 3 ), Triton X-100, iron, and Ca 
INTRODUCTION
Phospholipase A 2 (phosphatide 2-acylhydrolase; PLA 2 ; EC 3.1.1.4) hydrolyzes the sn-2 position of phospholipids to release free fatty acids and lysophospholipids, which are important precursors of bioactive substances including prostaglandins, leukotrienes, lysophosphatidic acid, and platelet-activating factor (PAF) (Schaloske and Dennis, 2006) . The PLA 2 family is largely divided on the basis of Ca 2+ requirement and cellular localization into 3 major subfamilies: the secretory PLA 2 (sPLA 2 ), cytosolic PLA 2 (cPLA 2 ), and Ca
2+
-independent PLA 2 (iPLA 2 ). sPLA 2 subfamily are stored in cytosolic granules or synthesized upon stimulation and then secreted extracellularly, whereas cPLA 2 and iPLA 2 subfamilies comprise intracellular enzymes. To date, this growing family of lipases has been categorized into 12 groups. Groups IIA, IVA, V, and VI have been extensively studied in the central nervous system (Green et al., 2008; Sun et al., 2010) . Group VI iPLA 2 , which does not require Ca
for catalysis, was purified and cloned in 1996. However, this enzyme was purified from rat brain homogenates by using multiple column chromatographic procedures with a very low yield (Molloy et al., 1998) . Reportedly, this enzyme exists in aggregates and occurs in several splice variants (Larsson et al., 1998; Tang et al., 1997) . Therefore, a wide variety of iPLA 2 activities has been found in different tissues (Tang et al., 1997) .
Increased PLA 2 activity and the resultant excessive production of pro-inflammatory lipid mediators potentially lead to neurological disorders, such as ischemia (Bonventre et al., 1997; Tabuchi et al., 2003) , Alzheimer's disease (Farooqui et al., 1997; 2006; Stephenson et al., 1996) , spinal cord injury (Anderson et al., 1985; Lukacova et al., 1996) , Parkinson's disease (Klivenyi et al., 1998; Tariq et al., 2001; Yoshinaga et al., 2000) , schizophrenia (Junqueira et al., 2004; Ross et al., 1997; 1999; Yao et al., 2000) , and multiple sclerosis (Kalyvas and David, 2004; Kalyvas et al., 2009; Pinto et al., 2003) . Besides, lysophosphatidylcholine, a product of PLA 2 , leads to demyelination (Dousset et al., 1995) . In the brain, the basal expression and activity of iPLA 2 are higher than those of cPLA 2 or sPLA 2 (Farooqui et al., 1999; Molloy et al., 1998) . Therefore, inhibition of iPLA 2 activity is an attractive approach for designing novel drugs to treat neurodegenerative disease-associated inflammation. However, until now, enzymes of the iPLA 2 subfamily have not been fully characterized and identified in nerve tissues. Therefore, identifying a form of PLA 2 in nerve tissues is essential to better understand and efficiently treat neurodegenerative diseases.
In this study, we purified a cytosolic iPLA 2 from bovine brain homogenates by using serial column chromatography. We classified this enzyme as a novel form of iPLA 2 on the basis of biochemical studies. It had an apparent molecular mass of 155 kDa and an isoelectric point of 5.3 on two-dimensional gel elec-trophoresis (2-DE). In addition, the purified iPLA 2 functioned at an optimal pH of 9.5 and its activity was inhibited by arachidonyl trifluoromethyl ketone (AACOCF 3 ), Triton X-100, iron ions, and millimolar concentrations of Ca
. This enzyme differed from the previously reported types of iPLA 2 from other tissues (Ackermann et al., 1994; 1995; Hazen and Gross, 1991; Hazen et al., 1990; Wolf and Gross, 1985) in that it was not inhibited by bromoenol lactone (BEL) and adenosine triphosphate (ATP). We expect this novel enzyme to play a crucial role in the production of eicosanoids.
MATERIALS AND METHODS
C]PA-GPC; 55.6 mCi/mmol) were purchased from Amersham Biosciences (Buckinghamshire, UK). Adenosine 5′-triphosphate disodium salt and Triton X-100 were purchased from Sigma-Aldrich (USA). Heparin-Sepharose CL-6B gels, Mono Q anion-exchange columns, Mono S cationexchange columns, and Superose 12 fast protein liquid chromatography (FPLC) gel-filtration columns were purchased from Pharmacia LKB Biotechnology (Sweden). DE52 gel was purchased from Whatman (UK). A phenyl-5PW hydrophobic column was purchased from Tosoh (Japan). Bovine brain tissue was obtained from a local slaughterhouse in Seoul and stored in a -70°C deep freezer. Immobiline DryStrip (pH 4-7, 7 cm), 2-DE reagents, including the IPGphor for first-dimension separation, and the silver staining reagent kit were purchased from Amersham Pharmacia Biotech (Sweden). Second-dimension separation was performed in a Mini Protein System from BioRad (USA).
iPLA 2 activity assay The substrate, 2-[1-
14
C]AA-GPC, was dried under nitrogen stream and subsequently resuspended in ethanol. The iPLA 2 activity assay was performed in 100 μl of the standard reaction buffer [200 mM Tris-HCl (pH 7.5) and 5 mM EDTA] containing iPLA 2 preparations and 0.45 nmol of the substrate (~55,000 cpm). Crude or purified iPLA 2 samples were incubated with the substrate at 37°C for 15-30 min. The assay was subsequently terminated by adding 560 μl of modified Dole's reagent (nheptane/isopropyl alcohol/1 N H 2 SO 4 as 400/190/10 [v/v/v]) and 110 μl of water, vortex mixing, and centrifuging. Then, 150 μl of the upper phase were transferred to a new microtube, to which 800 μl of n-heptane and silica gel (~5 mg) was added. The sample was vortex-mixed and centrifuged again. An aliquot (800 μl) of the supernatant was removed and added to 2.5 ml of β-scintillation solution (Insta Gel-XF) and counted for radioactivity with a Packard Tri-Carb liquid scintillation counter (Packard Instrument Co., USA). To investigate the optimal pH for iPLA 2 activity, the following buffers were prepared: 200 mM Tris-HCl (pH 7.5-8.5) and 200 mM glycine-NaOH (pH 9.0-10.5). The optimal pH for iPLA 2 activity was 9.5, but the assay was conducted at pH 7.5 to perform the experiments under physiological conditions. At this pH, iPLA 2 activity was 5.7-fold less than that at pH 9.5.
Preparation of enzyme extracts from bovine brain tissues
Frozen bovine brain tissues (1.2 kg) were cut into small pieces and homogenized with 5 volumes of homogenizing buffer (50 mM Tris-HCl [pH 7.5], 1 mM EDTA, 3 mM MgCl 2 , 50 mM KCl, and 10 mM 2-mercaptoethanol). The homogenates were centrifuged at 10,000 × g at 4°C for 10 min to remove the cell debris. Subsequently, the supernatants were centrifuged at 10,000 × g at 4°C for 1 h, and the pH of the resulting supernatants (S10) was adjusted to pH 5.0 with acetic acid (1:1 dilution in distilled water). These supernatants were again centrifuged at 10,000 × g at 4°C for 15 min. The precipitates (P10; pH 5.0) were resuspended in 25 mM Tris (pH 7.5), 1 mM EDTA, and 10 mM 2-mercaptoethanol, and then applied to a DEAE-cellulose anionexchange column.
Purification of iPLA 2
The resuspension (P10; pH 5.0) was loaded onto a DEAEcellulose anion-exchange column (DE52; 2.5 × 12.5 cm, 400 ml of bed volume) pre-equilibrated with buffer A (50 mM Tris-HCl [pH 7.5], 1 mM EDTA, and 10 mM 2-mercaptoethanol) by a peristaltic pump (Eyela, Japan) at a flow rate of 2 ml/min. After the column was washed with buffer A, the washed gel was eluted stepwise with buffer A containing 1.0 M NaCl. Thirty milliliters of the eluate were collected per fraction. Aliquots of each fraction were used for measurement of the iPLA 2 activity. The active fraction was pooled. The final KCl concentration was adjusted to 2 M KCl by adding KCl powder and mixing for 2 h at 4°C. The resultant pool was centrifuged at 100,000 × g for 1 h at 4°C. The supernatants were applied to a Phenyl-5PW hydrophobic column (21.3 mm × 15 cm) pre-equilibrated with 25 mM Tris (pH 7.5) buffer containing 1 mM EDTA, 10 mM 2-mercaptoethanol, and 1.0 M NaCl. The column was washed with the same buffer and then eluted at a flow rate of 5 ml/min with 150 ml of the same buffer in a linear gradient of buffer B [25 mM glycine-NaOH (pH 9.0), 1 mM EDTA, and 10 mM 2-mercaptoethanol]. Five milliliters of the eluate were collected per fraction. The active fraction was again pooled and the pH was adjusted to pH 6.2 with acetic acid (1:30 dilution in distilled water). The obtained solution was applied to a heparin-Sepharose CL-6B column (5 ml) pre-equilibrated with buffer S [50 mM CH 3 COONa (pH 5.6), 1 mM EDTA, and 10 mM 2-mercaptoethanol]. After washing with buffer S, the protein bound to the column was eluted with a linear gradient of buffer A containing 1.0 M NaCl. Three milliliters of the eluate were collected per fraction. The fractions with iPLA 2 activity were pooled and concentrated to ~7 ml by using 20-ml Centricon (Vivascience, UK) and applied to a Sephacryl S-300 gel-filtration column (26 mm × 60 cm) pre-equilibrated with buffer A containing 0.1 M NaCl. The protein bound to the column was eluted with buffer A containing 0.1 M NaCl at a flow rate of 1 ml/min. Five milliliters of the eluate were collected per fraction. The fractions with iPLA 2 activity were pooled and applied to a Mono S cation-exchange FPLC column (5.0 mm × 5.0 cm) pre-equilibrated with buffer S. After washing with buffer S, the protein was eluted with a linear gradient of buffer A containing 1.0 M NaCl at a flow rate of 1 ml/min. One milliliter of the eluate was collected per fraction. The fractions with iPLA 2 activity were pooled, diluted with buffer Q [25 mM Tris-HCl (pH 7.5), 1 mM EDTA, and 10 mM 2-mercaptoethanol], and applied to a Mono Q anion-exchange FPLC column (5.0 mm × 5.0 cm) pre-equilibrated with buffer Q. After washing with buffer Q, the protein was eluted at a flow rate of 1 ml/min with 20 ml of the buffer Q in a gradient of 0.0-1.0 M NaCl. The fractions containing iPLA 2 activity were pooled and concentrated to ~200 μl by using 4-ml Centricon (Vivascience) and applied to a Superose 12 FPLC gel-filtration column pre-equilibrated with buffer A containing 0.1 M NaCl. The protein was eluted with the buffer A containing 0.1 M NaCl at a flow rate of 0.5 ml/min. Five-hundred microliters of the eluate was collected per fraction. To estimate the apparent molecular
